new
assay
compos
ngen
rva
nanogen
inc
san
diego
ca
prodess
inc
waukesha
wi
pair
analytespecif
reagent
allow
multiplex
revers
transcriptas
polymeras
chain
reaction
rtpcr
electron
microarray
detect
influenza
viru
b
respiratori
syncyti
viru
b
human
parainfluenza
viru
type
evalu
comparison
hexaplex
prodess
multiplex
rtpcrenzym
hybrid
assay
comparison
includ
detect
respiratori
virus
wholeviru
stock
atcc
frozen
pediatr
respiratori
specimen
collect
children
hospit
wisconsin
octob
retest
six
indetermin
discrep
overal
agreement
improv
posit
neg
eight
specimen
still
discrep
rva
reagent
allow
rapid
sensit
specif
assay
detect
seven
common
respiratori
virus
children
mani
microbi
agent
caus
upper
lower
respiratori
infect
lri
includ
grow
list
virus
howev
major
identifi
caus
lri
children
viral
lri
adult
caus
virus
seven
common
virus
influenza
viru
b
respiratori
syncyti
viru
rsv
b
human
parainfluenza
viru
hpiv
type
human
metapneumoviru
b
adenovirus
serotyp
subspeci
f
human
coronavirus
other
rhinovirus
serotyp
also
caus
lri
children
adult
exact
proport
ill
still
determin
molecular
detect
common
communityacquir
respiratori
virus
wide
accept
gold
standard
term
sensit
specif
compar
cell
cultur
rapid
antigen
method
one
barrier
accept
molecular
test
high
cost
term
reagent
technician
time
addit
lri
caus
differ
respiratori
virus
differenti
reliabl
clinic
examin
multiplex
rtpcrenzym
hybrid
assay
eha
detect
seven
common
respiratori
virus
hexaplex
prodess
inc
waukesha
wi
use
wide
accur
rapid
costeffect
diagnosi
hospit
children
adult
immunocompromis
patient
analytespecif
reagent
asr
reagent
laboratori
use
develop
valid
assay
use
ngen
rva
asr
nanogen
inc
san
diego
ca
electron
microarray
nanochip
assay
method
laboratori
detect
differenti
amplifi
product
primer
sequenc
fieldtest
multiplex
rtpcr
primer
mixtur
use
hexaplex
assay
microarray
detect
platform
may
offer
advantag
midand
highthroughput
laboratori
decreas
technician
time
overal
assay
time
compar
rva
chip
nanochip
machin
eha
detect
method
multiplex
rtpcr
detect
influenza
viru
b
rsv
b
respiratori
specimen
collect
patient
admit
children
hospit
wisconsin
octob
describ
previous
cell
cultur
enzym
immunosorb
assay
directimmunofluoresc
assay
hexaplex
test
respiratori
virus
previous
carri
partial
report
twostep
rtpcr
carri
follow
manufactur
direct
prodess
cdna
product
reaction
split
use
two
separ
multiplex
pcr
one
reaction
use
hexaplex
supermix
assay
use
similar
rva
primer
mix
primer
lack
biotinyl
follow
amplif
materi
amplifi
hexaplex
supermix
underw
postpcr
purif
use
qiaquick
dna
purif
kit
qiagen
chatsworth
ca
follow
purif
amplifi
materi
use
eha
use
neutravidinco
microtit
plate
follow
amplif
amplifi
materi
dilut
cap
sampl
buffer
place
nanochip
instrument
postpcr
process
desalt
denatur
requir
autom
detect
respiratori
virus
carri
nanochip
electron
microarray
three
distinct
step
depict
fig
serial
dilut
atcc
strain
seven
respiratori
virus
test
hexaplex
rva
assay
determin
limit
detect
lod
use
whole
viru
tabl
hexaplex
demonstr
better
overal
analyt
sensit
viru
detect
rva
two
assay
within
log
unit
five
seven
virus
assay
appear
equal
tissu
cultur
infect
dose
tcid
ml
rva
assay
sensit
influenza
viru
b
tcid
ml
compar
hexaplex
captur
oligonucleotid
electron
deposit
four
pad
fifth
pad
unrel
captur
oligonucleotid
deposit
use
background
subtract
discrimin
report
allow
passiv
hybrid
amplicon
electron
address
five
pad
simultan
follow
sever
wash
cartridg
scan
biggest
differ
analyt
sensit
observ
hexaplex
log
unit
sensit
total
respiratori
specimen
patient
test
nasopharyng
swab
specimen
sampl
account
specimen
test
includ
bronchoalveolar
lavag
tracheal
sputum
throat
nasal
wash
miscellan
respiratori
sampl
sampl
test
posit
assay
sampl
posit
one
assay
sampl
origin
report
posit
hexaplex
neg
hexaplex
rva
retest
call
neg
presum
lowcopynumb
sampl
rna
degrad
time
three
sampl
previous
neg
hexaplex
upon
retest
posit
hexaplex
neg
rva
defin
neg
fals
posit
hexaplex
final
four
sampl
previous
posit
one
viru
hexaplex
posit
retest
differ
viru
hexaplex
neg
rva
sampl
evalu
includ
calcul
agreement
hexaplex
rva
seen
tabl
overal
agreement
high
confid
interv
ci
nearli
neg
sampl
lowest
agreement
sampl
correl
analyt
sensit
repeat
test
amplifi
pcr
product
posit
control
failur
one
run
result
three
rva
neg
sampl
determin
two
posit
one
indetermin
analyt
test
rva
indetermin
indetermin
hexaplex
test
repeat
test
sampl
demonstr
rva
indetermin
one
hexaplex
indetermin
posit
tabl
influenza
viru
b
rva
indetermin
becam
discrep
went
signaltonois
sn
ratio
sampl
went
sn
ratio
retest
hexaplex
result
remain
posit
went
optic
densiti
od
read
respect
rsv
hexaplexindetermin
sampl
posit
hexaplex
retest
rva
result
remain
neg
thu
retest
indetermin
result
three
new
discrep
test
sampl
origin
discrep
result
neg
rva
neg
hexaplex
howev
repeat
amplif
frozen
rna
sampl
use
either
standard
hexaplex
primer
mix
rva
primer
mix
one
sampl
resolv
hexaplex
fals
posit
remain
posit
indetermin
neg
posit
posit
hexaplex
rva
three
experiment
run
rva
assay
account
rva
discrep
suggest
specif
technic
error
pervas
one
repeat
test
rva
fals
neg
hexaplex
fals
neg
resolv
analysi
done
remain
five
unresolv
discrep
result
low
number
test
reagent
machineri
elucid
reason
abovement
technic
error
agreement
two
assay
shown
tabl
retest
discrep
analysi
agreement
two
assay
seven
virus
high
ci
ci
comparison
number
hour
technician
time
reagent
need
test
clinic
sampl
includ
posit
control
ie
sampl
two
multiplex
rtpcr
assay
hexaplex
eha
rva
shown
tabl
cost
rna
isol
kept
two
assay
manual
spin
column
reagent
cost
except
detect
chemistri
cost
equip
includ
eg
nanochip
although
autom
extract
would
save
consider
technician
time
add
startup
cost
reagent
cost
cost
autom
na
extract
includ
extractor
estim
assay
hexaplex
assay
slightli
less
expens
three
sampl
number
scenario
differ
small
manufactur
retail
cost
use
reagent
cost
rang
per
analyt
test
eha
electron
microarray
format
number
sampl
increas
cost
decreas
small
amount
detect
method
howev
rva
assay
need
significantli
less
technician
time
hexaplex
higher
sampl
number
almost
half
much
time
h
versu
h
estim
compar
manual
extract
autom
extract
demonstr
signific
reduct
technician
time
without
signific
decreas
cost
run
assay
time
run
assay
cut
almost
half
rva
assay
abl
test
sampl
h
technician
time
compar
h
hexaplex
possibl
higher
sampl
number
eg
electron
microarray
could
demonstr
higher
cost
save
common
communityacquir
respiratori
virus
caus
signific
morbid
mortal
demograph
subset
popul
group
highest
risk
includ
preschool
age
children
elderli
chronic
diseas
immunocompromis
rapid
accur
inexpens
pointofcar
test
abl
molecular
diagnosi
viral
respiratori
infect
becom
commonplac
wide
accept
major
medic
center
accept
partli
due
signific
evid
dramat
improv
sensit
compar
older
method
major
base
pcr
rtpcr
technolog
differ
endpoint
detect
strategi
although
amplif
method
explor
eg
nucleic
acid
sequencebas
amplif
none
wide
use
clinic
diagnost
laboratori
detect
respiratori
virus
time
medium
larg
multiplex
detect
strategi
six
pathogen
report
employ
eha
plate
use
hexaplex
capillari
electrophoresi
mass
spectrometri
luminex
bead
flowthrough
microarray
electron
microarray
current
fdaclear
molecular
amplif
method
detect
major
common
respiratori
virus
method
repres
inhousedevelop
assay
asr
technolog
allow
fairli
expens
test
medium
high
complex
laboratori
hexaplex
assay
first
larg
multiplex
clinic
assay
kind
introduc
almost
decad
ago
assay
target
seven
common
respiratori
virus
influenza
viru
b
rsv
b
wide
use
demonstr
excel
sensit
specif
exceed
older
method
hexaplex
use
eha
plate
pcr
product
detect
becom
timeconsum
costli
number
clinic
sampl
increas
sampl
one
solut
would
autom
pcr
product
detect
part
assay
nanogen
develop
electronicmicroarray
system
capabl
autom
multiplex
pcr
product
detect
microarray
use
analyz
sampl
across
run
data
shown
prodess
nanogen
codevelop
reagent
suitabl
use
platform
studi
undertaken
demonstr
agreement
multiplex
rtpcreha
hexaplex
rva
asr
use
nanochip
system
assay
method
laboratori
detect
seven
common
respiratori
virus
children
goal
includ
demonstr
lod
use
whole
viru
compar
cost
work
flow
assay
differ
level
util
eg
highvolum
laboratori
rva
demonstr
good
overal
lod
use
atcc
organ
good
standard
hexaplex
typic
singleprimerpair
pcr
assay
lod
tcid
ml
lower
five
seven
virus
demonstr
rva
overal
agreement
firstpass
test
typic
clinic
laboratori
test
two
assay
excel
pattern
discrep
result
suggest
may
much
higher
rva
reagent
use
regular
basi
best
demonstr
biggest
loss
analyt
sensit
observ
translat
decreas
clinic
sensit
three
clinic
run
retest
retest
agreement
two
assay
went
major
discrep
two
assay
detect
interestingli
rva
good
agreement
analyt
studi
hexaplex
low
lod
appear
correl
lowposit
hexaplex
sampl
od
lower
neg
rva
read
sn
sampl
like
unabl
statist
analysi
time
unclear
rva
ultim
agreement
hexaplex
clinic
test
may
clarifi
issu
importantli
agreement
neg
almost
lack
rva
fals
posit
subsequ
high
probabl
rva
posit
true
posit
allow
high
confid
clinic
set
unclear
major
discrep
rva
sampl
three
experiment
run
count
discrep
lot
reagent
use
run
specif
technic
error
either
nanochip
instrument
equip
could
identifi
reagent
equip
use
retest
sampl
yield
posit
result
retest
sampl
still
discrep
hexaplex
rva
costbenefit
time
util
studi
demonstr
hexaplex
least
expens
assay
run
even
sampl
per
day
chang
autom
extract
addit
higher
startup
cost
associ
electronicmicroarray
detect
howev
rva
assay
autom
detect
without
autom
extract
demonstr
signific
technician
time
save
reagent
becom
less
expens
methodolog
would
clear
advantag
highervolum
laboratori
current
price
structur
whether
cost
technician
time
import
would
help
determin
assay
would
use
clearli
fdaclear
pointofcar
test
devic
avail
detect
larg
number
pathogen
simultan
great
speed
accuraci
low
cost
final
goal
must
use
current
technolog
greatest
benefit
patient
societi
includ
use
inhousedevelop
test
asr
technolog
improv
academia
industri
three
major
area
import
step
stone
en
rout
final
goal
improv
sampl
prepar
method
eg
autom
nucleic
acid
extract
miniatur
use
microfluid
ii
improv
amplif
method
eg
multiplex
pcr
microfluid
direct
simultan
multipl
singletarget
amplif
postpcr
pool
product
prior
detect
iii
improv
detect
amplifi
target
eg
autom
larg
multiplex
detect
report
result
current
pcrbase
nucleic
acid
amplif
technolog
farthest
road
howev
mean
amplif
method
even
proteom
solut
might
develop
futur
effect
detect
respiratori
virus
method
use
small
clinic
sampl
abl
detect
mani
pathogen
sampl
concentr
tcid
ml
report
time
hour
paper
report
first
comparison
two
inhous
assay
major
differ
pcr
product
detect
strategi
manual
versu
autom
hexaplex
rva
inhous
assay
seven
common
communityacquir
respiratori
virus
repres
older
newer
step
improv
laboratori
diagnosi
mostli
hospit
sever
ill
patient
lri
ill
caus
virus
hexaplex
less
expens
small
medium
sampl
number
slightli
better
analyt
clinic
sensit
rva
assay
offer
increas
cost
save
number
clinic
sampl
increas
situat
limit
technician
time
autom
detect
assay
demonstr
high
level
agreement
hexaplex
rva
assay
need
optim
valid
clinic
situat
fresh
specimen
better
establish
perform
characterist
especi
detect
howev
initi
clinic
trial
perform
well
improv
analyt
lod
may
clinic
use
sampl
low
copi
number
elderli
immunocompromis
patient
